Search | Clinical Trials Finder

Conditions: Stage IV Non-Small Cell Lung Cancer
Interventions: Cetuximab in combination with Carboplatin/Gemcitabine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate; Biological · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2039
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions: Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 38
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more

Conditions: Stomatitis
Interventions: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 35 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Iza-bren, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Irvine, California • Orange, California • Edwards, Colorado + 22 more

Conditions: Breast Neoplasms, Pancreatic Neoplasms
Interventions: nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Non-small Cell Lung Cancer
Interventions: Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 11
States / cities: Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: CP-751,871, paclitaxel, carboplatin, erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: enfortumab vedotin, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 29
States / cities: Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more

Conditions: Non-Small Cell Lung Cancer
Interventions: PF-06747775, Palbociclib, Avelumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Orange, California + 10 more

Conditions: Breast Cancer, Lung Cancer
Interventions: yttrium Y 90-edotreotide; Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: MM-121, Erlotinib; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 16 more

Conditions: Locally Advanced or Metastatic NSCLC
Interventions: PBF-1129; Drug
Lead sponsor: Palobiofarma SL; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions: BT8009, Pembrolizumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more

Conditions: Non Small Cell Lung Cancer
Interventions: HM61713; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 20 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Beverly Hills, California • Burbank, California • Los Angeles, California + 11 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions: AFNT-211; Drug
Lead sponsor: Affini-T Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Other; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Erlotinib in combination with Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions: Osimertinib 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Santa Rosa, California • Las Vegas, Nevada • White Plains, New York

Search by objective public record fields.

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

PBF-1129 in Patients With NSCLC

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)